Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Breast Cancer Research and Treatment|July 16, 2013
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC studyMaria Afentakis, Mitch Dowsett, Ivana Sestak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trialAlistair Ring, Ivana Sestak, Michael Baum, et al.Cancer|November 3, 2011
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancerAman Buzdar, Charles Vogel, Lee Schwartzberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast CancerMitch Dowsett, Ivana Sestak, Richard Buus, et al.Journal of Cancer Research and Clinical Oncology|June 27, 2008
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or youngerYesim Eralp, Terry L Smith, Kadri Altundağ, et al.Cancer|May 27, 2003
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-upVasily Assikis, Aman Buzdar, Ying Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancerL Johnetta Blakely, Aman Buzdar, Hsiu-Yin Chang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2017
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial ImprovementChad Tang, Steven I Sherman, Mellanie Price, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancerAman Buzdar, Joyce A O'Shaughnessy, Daniel J Booser, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC studyMitch Dowsett, Jack Cuzick, Christopher Wale, et al.Pageof 3